Peter vestergaard - publications

309) Starup-Linde J, Lykkeboe S, Gregersen S, Hauge EM, Langdahl BL, Handberg Aa, 

         Vestergaard P. Differences in biochemical bone markers by diabetes type and the impact of 

         glucose. Bone 2015 (in press).

308) Morseth B, Graff-Iversen S, Jacobsen BK, Jørgensen L, Nyrnes A, Thelle D, Vestergaard P, 

        Løchen ML. Physical activity and atrial fibrillation in a general population: The Tromsø Study. 

        Eur Heart Journal 2015 (in press).

307) Starup-Linde J, Karahasanovic A, Vestergaard P, Eiken P. Diabetes øger risikoen for 

        frakturer. Ugeskr Laeger 2015 (in press).

306) Eiken P, Vestergaard P: Treatment of osteoporosis after alendronate or risedronate. 

        Osteoporosis Int 2015 (in press).

305) Thorsteinsson A-L, Vestergaard P, Pia Eiken. Compliance and persistence with treatment with 

        parathyroid hormone for osteoporosis. A Danish National Register Based Cohort Study. 

       Archives of Osteoporosis 2015; 10 (1); 35.

304) Petersen SB, Ström M, Maslova E, Granström C, Vestergaard P, Mølgaard C, Olsen SF: 

        Predicted vitamin D status during pregnancy in relation to offspring forearm fractures in 

        childhood: A study from the Danish National Birth Cohort. Br J Nutrition 2015 (in press).

303) Lalmohamed A, van Staa TP, Vestergaard P, Leufkens HGM, de Boer A, Emans P, Cooper C, 

        de Vries C. Statins and risk of lower limb revision surgery: the impact of differences in study 

        design using electronic health records from United Kingdom and Denmark. Am J Epidemiol 

        (in press).

302) Bronsveld HK, ter Braak B, Karlstad Ø, Vestergaard P, Starup-Linde J, Bazelier MT, de Bruin 

        ML, de Boer T, Siezen CLE, van de Water B; van der Laan JW, Schmidt M.Treatment with 

        insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis 

        of in vitro, animal and human evidence  Breast Cancer Research 2015; 17(1): 100 

301) Driessen JHM, van Onzenoort HAW, Starup-Linde J, Henry R, Burden AM, Neef C, van den 

        Bergh JP, Vestergaard P, de Vries F. Use of Glucagon-like-peptide 1 receptor agonists and risk 

        of fracture as compared to use of other anti-hyperglycemic drugs. Calcified Tissue Int 2015 (in 

        press).

300) Hansen L, Vestergaard P, Eiken P: Frakturforebyggelsesprogrammer kan forebygge 

        sekundære lavenergifrakturer. Ugeskr Læger 2015 (in press).

299) Driessen JHM, van Onzenroot H, Starup-Linde J, Henry RMA, Nees C, van den Bergh J, 

        Vestergaard P, de Vries F, Burden A. Use of dipeptidyl peptidase 4 inhibitors and fracture risk 

        compared to use of other anti-hyperglycemic drugs. Pharmacoepidemiology and Drug Safety 

        2015 (In press).

298) Eiken P, Vestergaard P: Medicinsk behandling af osteoporose hos mænd. Ugeskrift for Læger 

        2015 Aug 10;177(36). pii: V03150220.

297) Kruse C, Eiken P, Vestergaard P: Diuretics and Fracture Occurrence: A Matched Cohort 

        Study Based on 15 Years of National Danish Patient Data. Journal of Internal Medicine 2015 

        (in press).

296) Starup-Linde J, Vestergaard P: Management of endocrine disease: Diabetes and 

        osteoporosis - cause for concern? Eur J Endocrinol 2015; 173(3): R93-R99.

295) Vestergaard P: Primary hyperparathyroidism and nephrolithiasis. Annales d'Endocrinologie

        2015; 76: 116-119.

294) Hawley S, Wallace G, Javaid MK, Rubin KH, Judge A, Arden NK, Vestergaard P, 

        Eastell R, Diez-Perez A, Cooper C, Abrahamsen B. Incidence and predictors of multiple 

        fractures despite high adherence to oral bisphosphonates: a binational population-based cohort 

        study. JBMR 2015 (in press).

293) Westberg-Rasmussen S, Starup-Linde J, Gregersen S, Vestergaard P: Predictors of mortality 

        subsequent to a fracture in diabetes mellitus patients. Frontiers in Endocrinology, section 

        Genomic Endocrinology 2015 Apr 1;6:46. doi: 10.3389/fendo.2015.00046.

292) Eiken P, Vestergaard P: Oral bisphosphonates and colon cancer: an update. Therapeutic 

        Advances in Musculoskeletal Disease 2015; 74(4): 160-168.

291) Rolighed L, Rejnmark L, Sikjaer T, Heickendorff L, Vestergaard P, Mosekilde L, Christiansen 

        P: No beneficial effects of vitamin D supplementation on muscle function or quality of life in 

        primary hyperparathyroidism: results from a randomized controlled trial. Eur J Endocrinol 

        2015; May;172(5):609-17 .

290) Petersen S, Rasmussen M, Olsen S, Vestergaard P, Mølgaard C, Halldorsson T, Strøm M: 

        Maternal dietary patterns during pregnancy in relation to offspring forearm fractures: 

        Prospective study from the Danish National Birth Cohort. Nutrients 2015; 7(4): 2382-2400.

289) Bliddal H, Eriksen SA, Christensen R, Lorenzen T, Hansen MS, Østergaard M, Dreyer L, 

        Luta G, Vestergaard P. Adherence to methotrexate in rheumatoid arthritis treated by practice 

        vs. hospital based rheumatologists: A Danish nationwide cohort study. Arthritis 2015. Article 

        ID 915142, 7 pages. http://dx.doi.org/10.1155/2015/915142

288) Lomholt S, Amstrup AK, Moser E, Jacobsen NF, Mosekilde L, Vestergaard P, Rejnmark L. 

        Unexplained High BMD in DXA-Scanned Patients is Generalized Throughout the Skeleton 

        and Characterized by Thicker Cortical and Trabecular Bone. CTI 2015; 96(4):284-94 .

287) Starup-Linde J, Vestergaard P: Biochemical bone turnover markers in diabetes mellitus- a 

        systematic review. Bone 2015 Feb 24. pii: S8756-3282(15)00064-2.

286) Vestergaard P: Effect of Antiepileptic Drugs on Bone Health and Growth Potential in 

        Children with Epilepsy - a systematic review. Pediatric Drugs 2015; 17(2): 141-150. (DOI) 

        10.1007/s40272-014-0115-z

285) Kruse C, Eiken P, Vestergaard P: Hyponatremia and osteoporosis: Insights from the Danish 

        National Patient Registry. Osteoporosis Int 2015; 26(3): 1005-1016.

284) Petersen SB, Strøm M, Maslova E, Granström C, Vestergaard P, Mølgaard C, Olsen SF: 

        Maternal vitamin D status and offspring bone fractures: Prospective study over two decades in 

        Aarhus city, Denmark. PLOS ONE 2014; 9(12): e11434.

283) Gejl M, Starup-Linde J, Thomsen J, Gregersen S, Vestergaard P: Risk of cardiovascular 

        disease: The effects of diabetes and anti-diabetic drugs - a nested case-control study. Int J 

        Cardiology 2015;178:292-6.

282) Prieto-Alhambra D, Muñoz-Ortego J, De Vries F, Vosse D, Arden NK, Bowness P, Cooper C, 

         Diez-Perez A, and Vestergaard P: Ankylosing Spondylitis confers substantially increased risk 

        of clinical spine fractures: a nation-wide case-control study. Osteoporosis International 2015; 

        26(1): 85-91.

281) Vestergaard P: New strategies for osteoporosis patients previously managed with strontium 

        ranelate. Therapeutic Advances in Musculoskeletal Disease 2014; 6(6): 217-225.

280) Hansen L, Eriksen SA, Langdahl BL, Eiken PA, Brixen K, Abrahamsen B, Beck-Jensen JE, 

        Harsløf T, Vestergaard P. Subsequent Fracture rates in a Nationwide Population-Based 

        Cohort Study with a 10 year perspective. Osteoporosis Int 201; 26(2): 513-519.

279) Eriksen SA, Prietzel H, Ibsen JR, Lauritsen MB, Vestergaard P, Telléus GK. Bone Status in 

        Patients with Anorexia Nervosa and Relationship with Biochemical Findings. Danish Medical 

        Journal 2014; 61(11): A4940.

278) Prieto-Alhambra D, Lalmohamed A, Abrahamsen B, Arden NK, de Boer A, Vestergaard P, 

        de Vries F. Oral bisphosphonate use and total knee/hip implant survival: validation of results 

        in an external population-based cohort. Arthritis & Rheumatology 2014; 66(11): 3233-3240.

277) Starup-Linde J, Scheel-Thomsen J, Gejl M, Vestergaard P, Gregersen S. Liraglutide and 

        insulin are associated with a decreased risk of acute myocardial infarction in type 2 diabetes 

        mellitus patients. Journal of Diabetes and Metabolism 2014; 5(5): 389 

        (http://dx.doi.org/10.4172/2155-6156.1000389).

276) Starup-Linde J, Eriksen SA, Lykkeboe S, Handberg Aa, Vestergaard P: Biochemical markers 

        of bone turnover in diabetes patients—a meta-analysis, and a methodological study on the 

        effects of glucose on bone marker. Osteoporosis International: 2014; 25(6): 1697-1708.

275) Thorsteinsson AL, Vestergaard P, Eiken P. External auditory canal and middle ear 

        cholesteatoma and osteonecrosis in bisphosphonate-treated osteoporosis patients. A Danish 

        National Register Based Cohort Study and literature review. Osteoporosis Int 2014; 

        25(7):1937-44.

274) Abood A, Vestergaard P: Pregnancy Outcomes in Women with Primary Hyperparathyroidism. 

        Eur J Endocrinology 2014; 171(1): 69-76.

273) Omsland TK, Emaus N, Tell GS, Magnus JH, Ahmed LA, Holvik K, Center J, Forsmo S, 

        Gjesdal GS, Schei B, Vestergaard P, Eisman JS, Falch J, Tverdal Aa, Søgaard AJ, Meyer HE. 

           Mortality following the first hip fracture in Norwegian women and men 1999-2008. A 

        NOREPOS study. Bone 2014; 63:81-6.

272) Rolighed L, Rejnmark L, Sikjaer T, Heickendorff L, Vestergaard P, Mosekilde L, Christiansen 

        P. Vitamin D Treatment in Primary Hyperparathyroidism: a Randomized Placebo Controlled 

        Trial. JCEM 2014; 99(3): 1072-1080.

271) Munoz Ortega J, Vestergaard P, Blanch Rudio J, Wordsworth P, Judge A, Javaid MK, Arden 

        NK, Cooper C, Diez-Perez A, Prieto Alhambra D: Ankylosing spondylitis is associated with an 

        increased risk of vertebral and non-vertebral clinical fractures: a population-based cohort study. 

        JBMR 2014; 29(8): 1770-1776

270) Vestergaard P, Starup-Linde J: Diabetes, cancer and treatment – a mini-review. Current Drug 

        Safety 2013; 8(5): 292-295.

269) Starup-Linde J, Karlstad Ø, Aistrup Eriksen S, Vestergaard P, Bronsveld H, de Vries F, 

        Andersen M, Auvinen A, Haukka J, Hjellvik V, Bazelier M, de Boer A, Furu K, De Bruin ML. 

        CARING (CAncer Risk and INsulin analoGues): The association of Diabetes Mellitus and 

        Cancer Risk with focus on possible determinants- a systematic review and a meta-analysis. 

        Current Drug Safety 2013 ; 8(5): 296-332.

268) Karlstad Ø, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, Andersen 

        M, Auvinen A, Haukka J, Furu K, de Vries F, De Bruin ML. Use of insulin and insulin 

        analogues and risk of cancer - Systematic review and meta-analysis of observational studies. 

        Current Drug Safety 2013; 8(5): 333-348.

267) Knapen L, Dittrich S, de Vries F, Starup-Linde J, Vestergaard P, Henry R, Stolk L, Neef C, 

        Bazelier MT. Use of biguanides and the risk of colorectal cancer: a register-based cohort study. 

        Current Drug Safety 2013; 8(5): 349-356.

266) Peeters PJHL, Bazelier MT, Vestergaard P, Leufkens HGM, Schmidt MK, de Vries F, De 

        Bruin ML. Use of metformin and survival of diabetic women with breast cancer. Current Drug 

        Safety 2013; 8(5): 357-363.

265) Bazelier MT, de Vries F, Vestergaard P, Leufkens HGM, De Bruin ML. Use of 

        thiazolidinediones and risk of bladder cancer: disease or drugs? Current Drug Safety 2013; 

        8(5): 364-370.

264) Prieto-Alhambra D, Güerri-Fernández R, De Vries F, Lalmohamed A, Bazelier M, Starup 

        Linde J, Diez-Perez A, Cooper C, Vestergaard P: The association between HIV infection and 

        clinical fracture risk: a nation-wide casecontrol study. JAIDS 2014; 66(1):90-5.

263) Abrahamsen B, Vestergaard P: Proton pump inhibitor use and fracture risk - effect 

        modification by Histamine H1 receptor blockade. Observational case control study using 

        National Prescription Data. Bone 2013; 22;57(1):269-271.

262) Eiken P, Vestergaard P, Beck-Jensen JE: Fordele og ulemper ved postmenopausal hormonel 

        substitutions terapi – en status. Ugeskr Læger 2014; 176(6): 528-532

261) Abrahamsen B, Grove EL, Vestergaard P. Nationwide registry-based analysis of 

        cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate.  

        Osteoporosis Int 2014; 25(2): 757-762.

260) Lalmohamed A, Vestergaard P, de Boer A, Leufkens HGM, van Staa TP, de Vries F. Changes 

        in mortality patterns following total hip or knee replacement over the past two decades: a 

        nationwide cohort study. Arthritis and Rheumatism 2014; 66(2): 311-18.

259) Christensen AM, Brandsborg S, Vestergaard P, Laurberg S. Comparison of fracture risk 

        between patients with ileal pouch-anal anastomosis for ulcerative colitis and the general 

        population. Journal of Crohn's and Colitis 2013 Jul 18. doi:pii: S1873-9946(13)00239-0. 

        10.1016/j.crohns.2013.07.001.

258) Streym S, Møller UK, Rejnmark L, Heickendorff L, Mosekilde L, Vestergaard P. Maternal 

        and infant vitamin D status during the first 9 months of infant life – a cohort study. Eur J Clin 

        Nutr 2013 Oct;67(10):1022-1028. doi: 10.1038/ejcn.2013.152.

257) Greibe E, Lildballe DL, Streym D, Vestergaard P, Rejnmark L, Mosekilde L, Nexo E: 

        Cobalamin and haptocorrin in human milk and cobalamin-related variables in mother and 

        child: A nine month longitudinal study. Am J Clin Nutr 2013; 98(2):389-95.

256) Grove EL, Abrahamsen B, Vestergaard P: Heart failure in patients treated with 

        bisphosphonates. Journal of Internal Medicine 2013;274(4):342-50 .

255) Andersen T, Vestergaard P: Udredning og behandling af hypercalcæmi. Ugeskr Laeger 2014; 

        176(9): 846-850.

254) Lalmohamed A, Vestergaard P, Javaid K, de Boer A, Leufkens HGM, van Staa T, de Vries F. 

        Risk of gastrointestinal bleeding in patients undergoing total hip or knee replacement 

        compared with matched controls: a nationwide cohort study. Am J Gastroenterology 2013; 

        108(8):1277-85.

253) Bazelier MT, van Staa TP, Bentzen J, Vestergaard P, Uitdehaag BMJ, Leufkens HGH, 

        Stenager E, de Vries F. Multiple sclerosis and fracture risk: traditional meta-analysis versus 

        mega-analysis of individual patient data. OA Epidemiology 2013 Jul 22;1(1):9. 

252) Lalmohamed A, Vestergaard P, Cooper C, de Boer A, Leufkens HG, van Staa TP, de Vries F. 

        Timing of stroke in patients undergoing total hip replacement and matched controls: a 

         nationwide cohort study. Stroke. 2012 Dec;43(12):3225-9

251) Hansen L, Mathiesen AS, Vestergaard P, Petersen KD, Ehlers L. A Health Economic Analysis 

        of Osteoporotic Fractures; who carries the burden? Archives of Osteoporosis 2013; dec 8(1-2), 

        126.

250) Lalmohamed A, Vestergaard P, Jansen P, Grove EL, de Boer A, Leufkens HGM, van Staa T, 

        de Vries F. Prolonged outpatient vitamin K antagonist use and risk of venous 

        thromboembolism in patients undergoing total hip or knee replacement. Journal of Thrombosis 

        and Haemostasis 2013; 11(4):642-50.

249) Bazelier MT, de Vries F, Vestergaard P, Herings RMC, Gallagher AM, Leufkens HGM, van 

        Staa TP. Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. 

        Frontiers in Bone Research 2013; 4; article 11 (doi: 10.3389/fendo.2013.00011).

248) Jakobsen A, Laurberg P, Vestergaard P, Andersen S: Clinical risk factors for osteoporosis are 

        common among elderly people in Nuuk, Greenland. Int J Circumpolar Health 2013; 72: 19596 

        (http://dx.doi.org/10.3402/ijch.v72i0.19596).

247) við Streym S, Rejnmark L, Mosekilde L, Vestergaard P. No effect of season of birth on risk of 

        type 1 diabetes, cancer, schizophrenia, and ischemic heart disease, while some variations may 

        be seen for pneumonia and multiple sclerosis. Dermato-Endocrinology 2013 Apr 1;5(2):309-

16. doi: 10.4161/derm.22779.

246) Rolighed L, Vestergaard P, Heickendorff L, Sikjaer T, Rejnmark L, Mosekilde L, Christiansen 

        P: BMD improvements after operation for primary hyperparathyroidism. Langenbeck's 

        Archives of Surgery 2012; 398(1):113-20.

245) Güerri-Fernandez R, Vestergaard P, Carbonell C, Knobel H, Avilés FF, Castro AS, Nogués X, 

        Prieto-Alhambra D, Diez-Perez A. HIV infection is a strong independent risk factor for hip 

        fracture: a population-based cohort study. JBMR 2013; 28(6): 1259-1263.

244) Abood A, Vestergaard P: Increasing incidence of primary hyperparathyroidism in Denmark. 

        Danish Medical Journal 2013; 60(2): A4567 (resumé i Ugeskr Læger 2013; 175(6): 358).

243) Grove EL, Würtz M, Schwarz P, Jørgensen NR, Vestergaard P: Gastrointestinal events with 

        clopidogrel: a nationwide population-based cohort study. J General Internal Medicine 2013; 

        28(2): 216-222.

242) Vestergaard P, Eiken : Behandling af uræmisk osteodystrofi med lægemidler som påvirker 

        calcium-fosforomsætningen. Ugeskr Læger 2012; 174(47): 2931-2934.

241) Eiken P, Vestergaard P: Medicinsk behandling af osteoporose hos patienter med moderat til 

        svært nedsat nyrefunktion. Ugeskr Læger 2012; 174(47): 2926-2930.

240) Mosekilde L, Vestergaard P, Rejnmark L: The pathogenesis, treatment and prevention of 

        osteoporosis in men. Drugs 2013; 73(1): 15-29.

239) Vestergaard P, Prieto-Alhambra D, Javaid MK, Cooper C: Fractures in users of 

        antidepressants and anxiolytics and sedatives. Osteoporosis Int 2013; 24(2): 671-680.

238) Rizzoli R, Cooper C, Reginster J-Y, Abrahamsen B, Adachi JD, Brandi ML, Bruyère O, 

        Compston J, Ducy P, Ferrari S, Harvey N, Kanis JA, Karsenty G, Laslop A, Rabenda V, 

        Vestergaard P: Antidepressant medications and osteoporosis. Bone 2012; 51(3): 606-613.

237) Vestergaard P: Raloxifene for the treatment of postmenoapusal osteoporosis. Int J Clin 

        Rheumatol 2012; 7(3): 261-269.

236) Lalmohamed A, Vestergaard P, Klop C, Grove EL, de Boer A, Leufkens HGM, van Staa TP, 

        de Vries F: Timing of acute myocardial infarction in patients undergoing total hip / knee 

        replacement and matched controls: a nationwide cohort study. Archives of Internal Medicine 

        2012; 172 (16): 1229-1235.

235) Bazelier MT, van Staa T, Uitdehaag B, Cooper C, Leufkens H, Vestergaard P, Bentzen J, de 

        Vries F: A Simple Score for Estimating the Long-term Risk of Fracture in Patients with 

        Multiple Sclerosis. Neurology 2012; 79(9): 922-928.

234) Linde JS, Waldhauer E, Rolighed L, Mosekilde L, Vestergaard P: Renal stones and 

        calcifications in patients with primary hyperparathyroidism: associations with biochemical 

        variables. European Journal of Endocrinology 2012; 166: 1093-1100.

233) Bazelier MT, Vestergaard P, Gallagher AM, van Staa TP, Cooper C, Leufkens HGM, de Vries 

        F: Risk of Fracture with Thiazolidinediones: Disease or Drugs. Calcified Tissue Int 2012; 

        90(6): 450-457.

232) Bazelier MT, Bentzen J, Vestergaard P, Stenager E, Uitdehaag BMJ, Leufkens HGM, van 

        Staa TP, de Vries F: The Risk of Fracture in Incident Multiple Sclerosis Patients: the Danish 

        National Health Registers. Multiple Sclerosis Journal 2012; 18(11):1609-16.

231) Jørgensen NR, Grove E, Schwarz P, Vestergaard P: Clopidogrel and risk of osteoporotic 

        fractures – a nationwide cohort study. Journal of Internal Medicine 2012; 272(4):385-93.

230) Bazelier M, Gallagher A, van Staa TP, Cooper C, Leufkens HG, Vestergaard P, Leufkens, de 

        Vries F: Use of Thiazolidinediones and Risk of Osteoporotic Fracture: Disease or Drugs? 

        Pharmacoepidemiology and Drug Safety 2012; 21(5): 507-514.

229) Schwarz P, Jørgensen NR, Mosekilde L, Vestergaard P: Effects of increasing age, dosage and 

        length of PTH treatment on BMD increase – a meta-analysis. Calcified Tissue Int 2012; 90(3): 

        165-173.

228) Vestergaard P: Denosumab – behandling af osteoporose og cancer. Ugeskrift for Læger 2012 

        ;174(12): 781-781.

227) Vestergaard P: Acute myocardial infarction (AMI) and atherosclerosis of the coronary arteries 

        in patients treated with drugs against osteoporosis – calcium in the vessels and not the bones? 

        Calcified Tissue International 2012; 90(1): 22-29.

226) Graversen D, Vestergaard P, Stochholm K, Gravholt CH, Jørgensen JOL. Mortality in 

        Cushing's Syndrome: a systematic review and meta-analysis. Eur J Intern Med 2012; 23(3): 

        278-282.

225) Bazelier MT, van Staa TP, Uitdehaag B, Cooper C, Leufkens HGM, Vestergaard P, Heerings 

        R, de Vries F. Risk of Fractures in Patients with Multiple Sclerosis: a population-based 

        cohort study. Neurology 2012; 78 (24): 1967-1973.

224) Vestergaard P: Occurrence of gastrointestinal cancer in users of bisphosphonates and other 

        anti-resorptive drugs against osteoporosis. Calcified Tissue Int 2011; 89(6): 434-441.

223) Bazelier MT, de Vries F, Bentzen J, Vestergaard P, Leufkens HGM, van Staa TP, Koch-

        Henriksen N: Incidence of Fractures in Patients with Multiple Sclerosis: the Danish National 

        Health Registers. Multiple Sclerosis Journal 2012; 18(5): 622-627.

222) Vestergaard P: Diabetes and bone. Journal of Diabetes & Metabolism 2011 

        (http://www.omicsonline.org/2155-6156/2155-6156-S1-001.pdf).

221) Christensen SE, Nissen PH, Vestergaard P, Mosekilde L. Familial Hypocalciuric 

        Hypercalcaemia (FHH)- a review. Current Opinion in Endocrinology, Diabetes, and Obesity 

        2011; 18: 359-370.

220) Vestergaard P: Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate. 

        Calcified Tissue Int 2011; 89(4): 265-270.

219) Vestergaard P, Hermann P, Beck Jensen J-E, Eiken P, Mosekilde L: Effects of paracetamol, 

        non-steroidal anti-inflammatory drugs (NSAID), acetylsalicylic acid (ASA), and opiods on 

        BMD and risk of fractures – results of the Danish Osteoporosis Prevention Study (DOPS). 

        Osteoporosis Int 2012; 23(4): 1255-1265.

218) Vestergaard P, Støen OG, Swenson JE, Mosekilde L, Heickendorff L, Frøbert P: Vitamin D 

        status and bone and connective tissue turnover in brown bears (Ursus arctos) during 

        hibernation and the active state. Plos One 2011; 6(6): e21483 

        (doi:10.1371/journal.pone.0021483).

217) Bazelier M, van Staa T, Uitdehaag B, Cooper C, Leufkens H, Vestergaard P, Bentzen J, de 

        Vries F. The Risk of Fracture in Patients with Multiple Sclerosis: the UK General Practice 

        Research Database. JBMR 2011; 26(9): 2271-2279.

216) Vestergaard P, vid Streym Thomsen S: Medical treatment of primary, secondary, and tertiary 

        hyperparathyroidism. Current Drug Safety 2011; 6(2): 108-113.

215) Rejnmark L, Vestergaard P, Mosekilde L: Nephrolithiasis and renal calcifications in primary 

        hyperparathyroidism. JCEM 2011; 96(8): 2377-2385.

214) Schwarz P, Jørgensen NR, Mosekilde L, Vestergaard P: The evidence for efficacy of 

        osteoporosis treatment in men with primary osteoporosis – a systematic review and meta-

        analysis of anti-resorptive and anabolic treatment in men. J Osteoporosis 2011 Article ID 

        259818, 9 pages, 2011. doi:10.4061/2011/259818.

213) Vestergaard P, Schwarz P, Steinberg TH, Jørgensen NR: Use of the oral platelet inhibitors 

        dipyridamole and acetylsalicylic acid is associated with increased risk of fracture. Int J Cardiol 

        2012 Sep 20;160(1):36-40.

212) Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L. Oral bisphosphonate use 

        increases the risk for inflammatory jaw disease: A cohort study. J Oral Maxillofacial Surg 

        2012; 70(4): 821-829.

211) Amstrup AK, Rejnmark L, Sikjaer T, Rolighed L, Vestergaard P, Heickendorff L, Mosekilde 

        L: Vitamin D status, Physical Performance and Body Mass in Patients Surgically Cured for 

        Primary Hyperparathyroidism Compared with Healthy Controls - A Cross-sectional Study. 

        Clinical Endocrinology 2011;(74)1:130-136. 

210) Schwarz P, Jørgensen NR, Jensen LT, Vestergaard P: Bone Mineral Density difference 

        between Right and Left  Hip during Ageing. Eur Geriatric Medicine 2011; 2: 82-86.

209) Vestergaard P, Fischer L, Mele M, Mosekilde L, Christiansen P: Use of bisphoshonates and 

        risk of breast cancer. Calcified Tissue Int 2011; 88(4): 255.

208) Rejnmark L, Brot C, Vestergaard P, Mosekilde L: Increased fracture risk in normocalcaemic 

        postmenopausal women with high parathyroid hormone levels: a 16-yrs follow-up study. 

        Calcified Tissue Int 2011; 88(3): 238-245.

207) Vestergaard P, Rejnmark L, Mosekilde L: Are antiresorptive drugs effective against fractures 

        in patients with diabetes? Calcified Tissue Int 2011; 88(3): 209-214.

206) Vestergaard P, Rejnmark L, Mosekilde L: Risk of femoral shaft and subtrochanteric fractures 

        among users of bisphosphonates and raloxifene. Osteoporosis Int 2011; 22(3): 993-1001.

205) Rejnmark L, Heickendorff L, Vestergaard P, Mosekilde L: Determinants of plasma PTH and 

        their implication for defining a reference interval. Clinical Endocrinology 2011; 74(1): 37-41.

204) Amstrup AK, Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L: Effects of 

        smoking on severity of disease in primary hyperparathyroidism. Calcified Tissue Int 2010 

        87(5): 406-413.

203) Vestergaard P: How may osteoporosis be prevented in individuals with diabetes. Diabetes 

        Management 2010; 12: 53-60 (http://viewer.zmags.com/publication/ad06b13c#/ad06b13c/60 ).

202) Maraldo M, Vestergaard P, McMurdo MET, Schwarz P: The Evidence for anti-resorptive 

        osteoporosis treatment in the elderly and old. Eur Geriatric Med 2010; 1(5): 279-292.

201) Rejnmark L, Vestergaard P, Mosekilde L: Denosumab – en ny effektiv 

        osteoporosebehandling. Ugeskrift for Læger 2011; 173(5); 346-349.

200) Vestergaard P, Rejnmark L, Mosekilde L: Risk of fractures associated with treatment for 

        benign prostate hyperplasia in men. Osteoporosis Int 2011; 22: 731-737.

199) Bofill NG, Husted LB, Harsløf T, Tofteng CL, Eiken P, Vestergaard P, Langdahl BL. Effects 

        of COLIA1 Polymorphisms and Haplotypes on Perimenopausal Bone Mass, Postmenopausal 

        Bone Loss and Fracture Risk. Osteoporosis Int 2011; 22(4): 1145-1156.

198) Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L:Stroke in relation to use of 

        raloxifene and other drugs against osteoporosis. Osteoporosis Int 2011; 22(3): 993-1001.

197) Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L: Risk of atrial fibrillation 

        associated with use of bisphosphonates and other drugs against osteoporosis – a cohort study. 

        Calcified Tissue Int 2010; 86(5): 335-342.

196) Pouwels S, Lalmohamed A, van Staa T, Cooper C, Souverein P, Leufkens B, Rejnmark L, de 

        Boer A, Vestergaard P, de Vries F. Use of organic nitrates and the risk of hip fracture: a 

        population-based case-control study. JCEM 2010; 95(4): 1924-1931.

195) Beck-Nielsen SS, Brusgaard K, Brixen K, Jensen TK, Brock-Jacobsen B, Poulsen MR, 

        Vestergaard P, Poulsen S, Haubek D, Gjørup H, Hintze H, Andersen MG, Gram J. Phenotype 

        presentation of hypophosphatemic rickets in adults. Calcified Tissue Int 2010; 87(2): 108-119.

194) Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L: Gastric and esophagus 

        events before and during treatment of osteoporosis. Calcified Tissue Int 2010; 86(2): 110-115.

193) Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L: Use of bisphosphonates 

        and raloxifene and risk of deep venous thromboembolism and pulmonary embolism. 

        Osteoporosis Int 2010; 21(9): 1591-1597.

192) Vestergaard P, Rejnmark L, Mosekilde L: High dose treatment with vitamin A analogues and 

        risk of fractures. Arch Dermatology 2010; 146(5): 478-482.

191) Vestergaard P, vid Streym Thomsen S: Treating postmenopausal osteoporosis in women at 

        increased risk of fracture: critical appraisal of bazedoxifene. Int J Womens Health 2010; 1: 97-

        103.

190) Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L, Mosekilde L. 

        Reduced pre-diagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested 

        case-control study. Cancer Epidemiology, Biomarkers & Prevention 2009; 18(10): 2655-2660.

189) Jørgensen L, Vik A, Emaus N, Brox J, Hansen J-B, Mathiesen E, Vestergaard P: Bone loss in 

        relation to serum levels of osteoprotegerin and nuclear factor-kB ligand. The Tromsø Study. 

        Osteoporosis Int 2010; 21: 931-938.

188) Vestergaard P, Rejnmark L, Mosekilde L: Loss of life-years after a hip fracture – effects of 

        age and gender. Acta Orthop 2009; 80(5): 525-530.

187) Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L: Simvastatin does not affect vitamin 

        D status, but low vitamin D levels are associated with dyslipidemia: results from a randomised, 

        controlled trial. Int J Endocrinology 2010 (PMID: 20016680).

186) Abrahamsen B, Vestergaard P: Declining incidence of hip fractures and the extent of use of 

        anti-osteoporotic therapy in Denmark 1997-2006. Osteoporosis Int 2010; 21(3): 373-380.

185) Rubeck KZ, Bertelsen S, Vestergaard P, Jørgensen JOL. Impact of Growth Hormone (GH) 

        Substitution on Exercise Capacity and Muscle Strength in GH-Deficient Adults: A Meta-

        Analysis of Blinded, Placebo-Controlled Trials. Clinical Endocrinology 2009; 71(6): 860-866.

184) vid Streym Thomsen S, Vestergaard P: Do the Drugs Used to Treat Rheumatic Disorders 

        Induce Bone Fragility? A Review. CML Rheumatology 2009; 28(1): 1-8.

183) Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P: Hip fracture patients at risk of 

        second hip fracture: A nationwide population-based cohort study of 169,145 cases during 

        1977-2001. JBMR 2009; 24(7): 1299-1307.

182) Vestergaard P, Rejnmark L, Mosekilde L: Osteoarthritis and risk of fractures. Calcified Tissue 

        Int 2009; 84(4): 249-256.

181) Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Rejnmark L, Brixen K, Mosekilde 

        L :Skeletal consequences of familial hypocalciuric hypercalcaemia versus primary 

        hyperparathyroidism. Clin Endocrinol 2009; 71(6): 798-807.

180) Vestergaard P, Mosekilde L: Medicinsk behandling af patienter med primær 

        hyperparathyreoidisme. Ugeskr Læger 2009; 171(33): 2284-2287.

179) Vestergaard P, Rejnmark L, Mosekilde L: Hypertension is a risk factor for fractures. Calcified 

        Tissue International 2009; 84(2): 103-111.

178) Vestergaard P, Rejnmark L, Mosekilde L: Diabetes and its complications and their 

        relationship with risk of fractures in type 1 and 2 diabetes. Calcified Tissue Int 2009; 84(1): 45-

        55.

177) Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Rejnmark L, Brixen K, Mosekilde 

        L: Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and PTH in familial hypocalciuric 

        hypercalcaemia (FHH) and primary hyperparathyroidism (PHPT). Eur J Endocrinol 2008; 

        159(6): 719-727.

176) Vestergaard P: Bone Metabolism in type 2 diabetes and role of thiazolidinediones. Current 

        Opinion in Endocrinology and Diabetes 2009; 16(2): 125-131

175) Vestergaard P. Fracture risks of antidepressants. Expert Review of Neurotherapeutics 2009; 

        9(1): 137-141.

174) Vestergaard P, Rejnmark L, Mosekilde L: The effects of depot medroxyprogesterone acetate 

        and use of intrauterine devices on fracture risk in Danish women. Contraception 2008; 78(6): 

        459-464.

173) Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk in very young women using combined 

        oral contraceptives. Contraception 2008; 78(5): 358-364.

172) Vestergaard P: Pain-relief medication and risk of fractures. Current Drug Safety 2008; 3(3 - 

        September); 199-204.

171) Vestergaard P: Skeletal effects of systemic and topical corticosteroids. Current Drug Safety 

        2008; 3(3 - september), 190-194.

170) Vestergaard P: Skeletal effects of central nervous system active drugs: anxiolytics, sedatives, 

        antidepressants, lithium and neuroleptics. Current Drug Safety 2008; 3(3 - september), 185-

        190.

169) Vestergaard P: Skeletal effects of drugs to treat cancer. Current Drug Safety 2008; 3(3 – 

        september), 173-178.

168) Vestergaard P: Changes in bone turnover, bone mineral and fracture risk induced by drugs 

        used to treat epilepsy. Current Drug Safety 2008; 3(3 – September), 168-173.

167) Mosekilde L, Vestergaard P, Langdahl B: Fracture prevention in postmenopausal women. Am 

        Fam Physician 2008; 77(10): 1447-1448

166) Gissel T, Rejnmark L, Mosekilde L, Vestergaard P: Intake of vitamin D and risk of breast 

        cancer - a meta-analysis. Journal of Steroid Biochemistry and Molecular Biology 2008; 111(3-

        5): 195-199

165) Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk in patients with different types of 

        cancer. Acta Oncol 2009; 48(1): 105-115.

164) Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Brixen K, Mosekilde L: 

        Discriminative power of three indices of renal calcium excretion for the distinction between 

        familial hypocalciuric hypercalcemia and primary hyperparathyroidism: A follow-up study on 

        methods. Clin Encocrinol (Oxf) 2008; 69(5): 713-720.

163) Vestergaard P, Rejnmark L, Mosekilde L: Effect of tamoxifen and aromatase inhibitors on the 

        risk of fractures in women with breast cancer. Calcified Tissue Int 2008; 82(5): 334-340.

162) Frohnert J, Jönsson ÅL, Christiansen P, Vestergaard P: Kan isoleret måling af calcitonin 

        erstatte pentagastrintest? Ugeskr Læger 2008; 170(41): 3238-3242.

161) Hagenau T, Vest R, Gissel TN, Poulsen CS, Erlandsen M, Mosekilde L, Vestergaard P: 

        Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: An ecologic 

        meta- regression analysis. Osteoporosis Int 2009; 20(1): 133-140.

160) Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with different types of oral 

        corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif 

        Tissue Int 2008; 82(4): 249-257.

159) Bjarnason NH, Hitz M. Jørgensen NR, Vestergaard P: Adverse bone effects during 

        pharmacological breast cancer therapy. Acta Oncol 2008; 47(4): 747-754.

158) Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L: Plasma 1,25(OH)2D levels 

        decrease in postmenopausal women with hypovitaminosis D. Eur J Endocrinol 2008; 158: 571-

        576.

157) Andersen LV, Vestergaard P, Deichgraeber P, Lindholt JS, Mortensen LS, Frost L: Warfarin 

        for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a 

        meta-analysis. Heart 2008; 94(12): 1607-1613.

156) Vestergaard P, Rejnmark L, Mosekilde L: Selective serotonin reuptake inhibitors and other 

        antidepressants and risk of fracture. Calcified Tissue Int 2008; 82(2): 92-101.

155) Rejnmark L, Vestergaard P, Brot C, Mosekilde L: Parathyroid response to vitamin D 

        insufficiency:  relations to bone, body composition, and to life style characteristics. Clin 

        Endocrinol 2008; 69(19): 29-35.

154) Vestergaard P, Rejnmark L, Mosekilde L: Osteoporose og frakturer, der er associeret med 

        lægemidler. Ugeskr Læger 2008; 170(18): 1550-1555.

153) Vestergaard P, Rejnmark L, Mosekilde L: Anxiolytics and sedatives and risk of fractures – 

        effects of half-life. Calcified Tissue Int 2008; 82(1): 34-43

152) Rejnmark L, Vestergaard P, Charles P, Hermann AP, Brot C, Eiken P, Mosekilde L: Dietary 

        intake of folate but not vitamin B2 or B12 is associated with increased bone mineral density 5-

        years after the menopause: results from a 10 year follow-up study in early postmenopausal 

        women. Calcified Tissue Int 2008; 82(1): 1-11.

151) Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L. 

        Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin 

        Endocrinol 2008; 68(5): 707-715.

150) Vestergaard P: Adverse effects of drugs on bone and calcium metabolism/physiology. Clinical 

        reviews in Bone & Mineral Metabolism 2008: 6 (1-2): 1-16.

149) Vestergaard P, Rejnmark L, Mosekilde L: Stærkt stigende hyppighed af hoftebrud i Danmark 

        fra 1977 til 1999. Ugeskrift for Læger 2008; 170(8): 621-623.

148) Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with Parkinsonism and 

        anti-Parkinson drugs. Calcified Tissue Int 2007: 81(3): 153-161.

147) Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk in patients with chronic lung diseases 

        treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest 2007; 132: 1599-

        1607.

146) Vestergaard P, Jørgensen NR, Schwarz P, Mosekilde L: Effects of treatment with fluoride on 

        bone mineral density and fracture risk - a meta-analysis. Osteoporosis Int 2008; 19(3): 257-

        268.

145) Vestergaard P, Rejnmark L, Mosekilde L: Has mortality after a hip fracture increased? J Am 

        Geriatrics Soc 2007: 55(11): 1720-1726.

144) Vestergaard P: Fracture risk associated with drugs - a search for candidate drugs in the same 

         way as for candidate genes. Therapy 2007; 4(4): 407-422.

143) Vestergaard P, Rejnmark L, Mosekilde L: Increased mortality in patients with a hip fracture – 

        effect of pre-morbid conditions and post-fracture complications. Osteoporosis Int 2007; 

        18(12): 1583-1593.

142) Gissel T, Poulsen CS, Vestergaard P: Adverse effects of antiepileptic drugs on bone mineral 

        density in children. Expert Opinion on Drugs 2007; 6(3): 267-278.

141) Vestergaard P: Antiresorptive therapy for the prevention of postmenopausal osteoporosis: 

        when should treatment begin? Womens Health 2007; 18(1): 13-16.

140) Vestergaard P, Eiken P: Behandling og forebyggelse af osteoporose hos patienter med nedsat 

        nyrefunktion - en statusartikel. Ugeskr Læger 2008; 170(4): 227-230.

139) Moosgaard B, Vestergaard P, Heickendorff L, Mosekilde L: Plasma 1,25-dihydroxyvitamin D 

        levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and 

        renal function. Clin Endocrinol (Oxf). 2007; 66(1): 35-42.

138) Mosekilde L, Langdahl BL, Rejnmark L, Vestergaard P: Nytte af calcium- og D-

        vitamintilskud efter WHI-studiet. Ugeskrift for Læger 2007; 169(39): 3273-3276.

137) Vestergaard P, Vestergaard EM, Brockstedt H, Christiansen P: Codon Y791F mutations in a 

        large kindred? Is prophylactic thyroidectomy always indicated? World J Surg 2007; 31(5): 

        996-1001.

136) Vestergaard P: Osteoporosis and fracture risk in patients with diabetes. Sociedad 

        Iberoamericana de Información Científica (SIIC) Salud 2006; November(11): 1.

135) Vestergaard P, Mosekilde L. Ingen effect af calciumtilskud på knoglemineraltætheden hos 

        børn – Gennemgang af et Cochrane-review. Ugeskr Laeger 2007;169(26-32): 2512-2515.

134) Rasmussen K, Larsen LP, Arveshoug A, Theil Nielsen J, Vestergaard P, Rønning H, 

        Mosekilde L, Christiansen P: Predictive value of parathyroid scintigraphy in the preoperative 

        evaluation of patients with primary hyperparathyroidism. Scand J Surg 2006; 95: 199-204.

133) Vestergaard P: Discrepancies in bone mineral density and fracture risk in patients with type 1 

        and type 2 diabetes - a meta-analysis. Osteoporosis Int 2007; 18(4): 427-444.

132) Rejnmark L, Vestergaard P, Mosekilde L: Fracture risk in patients treated with amiodarone or 

        digoxin for cardiac arrhythmias: a nation-wide case-control study. Osteoporosis Int 2007;    

       18(4): 409-417.

131) Rejnmark L, Vestergaard P, Mosekilde L: Decreased fracture risk in users of organic nitrates: 

        a nation-wide case-control study. J Bone Mineral Res 2006; 21(11): 1811-1817.

130) Moosgaard P, Vestergaard P, Heickendorff L, Melsen F, Mosekilde L: Plasma 25-

        hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma 

        secretion in primary hyperparathyroidism: a cross-sectional study. Eur J Endocrinol. 

        2006; 155(2): 237-244.

129) Rejnmark L, Vestergaard P, Mosekilde L: Fracture risk in users of oral anticoagulants: a 

         nation-wide case-control study. International Journal of Cardiology 2007; 118(3): 338-344.

128) Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P. Effects of parathyroid hormone alone 

         or in combination with antiresorptive therapy on bone mineral density and fracture risk – a 

         meta-analysis. Osteoporosis Int 2007; 18(1): 45-57.

127) Vestergaard P: Current Pharmacological Options for the Management of Primary 

        Hyperparathyroidism. Drugs 2006: 66 (17); 2189-2211.

126) Vestergaard P: Postmenopausal Hormone therapy. Current Women’s Health Reviews 2006; 

        2(3): 197-205.

125) Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with use of non-steroidal 

        anti-inflammatory drugs (NSAID), acetylsalicylic acid, and acetaminophen, and the effects of 

        rheumatoid arthritis and osteoarthritis. Calcified Tissue Int 2006; 79 (2): 84-95.

124) Vestergaard P, Rejnmark L, Mosekilde L: Proton pump inhibitors, histamine H2 receptor 

        antagonists, and other antacid medications, and the risk of fracture. Calcified Tissue Int 2006; 

        79 (2): 76-83.

123) Vestergaard P, Rejnmark L, Mosekilde L: Methotrexate, azathioprine, cyclosporine, and risk 

        of fractures. Calcified Tissue Int 2006; 79 (2): 69-75.

122) Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with use of morphine and 

        opiates. J Intern Med 2006; 260: 76-87.

121) Rejnmark L, Vestergaard P, Mosekilde L: Statin but not Non-Statin Lipid-Lowering Drugs 

        Decrease Fracture Risk: A Nation-Wide Case-Control Study. Calcified Tissue Int 2006: 79(1): 

        27-36.

120) Frost L, Andersen LV, Vestergaard P, Husted S, Mortensen LS: Trend in risk of stroke in 

        patients with a hospital diagnosis of nonvalvular atrial fibrillation: National cohort study in 

        Denmark, 1980-2002. Neuroepidemiology 2006; 26: 212-219.

119) Rejnmark L, Lauridsen AL, Vestergaard P, Brot C, Mosekilde L, Nexø E: Vitamin D and its 

        binding protein Gc: long-term variability in peri- and post-menopausal women with and 

        without hormone replacement. Scand J Clin Lab Invest 2006; 66(3): 227-238.

118) Vestergaard P, Rejnmark L, Mosekilde L: Oral contraceptive use and risk of fractures. 

        Contraception. 2006; 73(6): 571-576.

117) Abrahamsen B, Vestergaard P, Rud B, Bärenholdt O, Jensen JEB, Nielsen SP, Mosekilde L, 

        Brixen K. year absolute risk of osteoporotic fractures according to BMD T-score at 

        menopause. The Danish Osteoporosis Prevention Study. JBMR 2006; 21: 796-800.

116) Vestergaard P, Rejnmark L, Mosekilde L: Anxiolytics, sedatives, antidepressants, 

        neuroleptics, and risk of fracture. Osteoporosis Int 2006; 17(6): 807-816.

115) Frost L, Andersen LV, Vestergaard P, Husted S, Mortensen LS: Trend in mortality after stroke 

        with atrial fibrillation. Am J Med 2007; 120(1):47-53.

114) Vestergaard P, Rejnmark L, Mosekilde L: Fracture reducing potential of hormone replacement 

        therapy on a population level. Maturitas 2006; 54: 285-293.

113) Rejnmark L, Vestergaard P, Charles P, Hermann AP, Brot C, Eiken P, Mosekilde L: No effect 

        of vitamin K1 intake on bone mineral density and fracture risk in perimenopausal women. 

        Osteoporosis Int 2006; 17(8): 1122-1132.

112) Rejnmark L, Vestergaard P, Mosekilde L: Treatment with beta-blockers, ACE-inhibitors, and 

        calcium-channel blockers is associated with a reduced fracture risk: a nation-wide case-control 

        study. J Hypertens 2006; 24(3): 581-589.

111) Vestergaard P, Rejnmark L, Mosekilde L: Socioeconomic aspects of fractures within universal 

        public health care: A nationwide case-control study from Denmark. Scandinavian Journal of 

        Public Health 2006; 34 (4): 371-377.

110) Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L: Loop diuretics 

        increase bone turnover and decrease bone mineral density in osteopenic postmenopausal 

        women – results from a randomised controlled study with bumetanide. J Bone Mineral Res 

        2006; 21(1): 163-170.

109) Rejnmark L, Vestergaard P, Mosekilde L: Fracture risk in patients treated with loop diuretics. 

        J Intern Med 2006; 259 (1): 117-124.

108) Frost L, Hune LJ, Vestergaard P: Overvægt, fedme og risiko for atrieflimren eller atrieflagren 

        – sekundærpublikation. Ugeskrift for Læger 2005: 167(37): 3507-3509 (dobbeltpublikation af 

        nr 100).

107) Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. 

        Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in 

        primary hyperparathyroidism. Clinical Endocrinology 2005; 63: 506-513.

106) Frost L, Vestergaard P. Alkohol og risiko for atrieflimren eller atrieflagren – 

        sekundærpublikation. En kohorteundersøgelse. Ugeskrift for Læger 2005; 167(35): 3308-3310. 

        (dobbeltpublikation af nr. 90).

105) Frost L, Vestergaard P, Mosekilde L: Hypertyroidisme og risiko for atrieflimren eller 

        atrieflagren – sekundærpublikation. Ugeskrift for Læger 2005; 167(35): 3305-3307 

        (dobbeltpublikation af nr. 68).

104) Vestergaard P: Antiresorptive Therapy for the Prevention of Postmenopausal Osteoporosis: 

        When Should Treatment Begin? Treatments in Endocrinology 2005; 4(5): 263-277.

103) Vestergaard P: Epilepsy, osteoporosis and fracture risk – a meta-analysis. Acta Neurologica 

         Scandinavica 2005; 112(5): 277-286.

102) Vestergaard P, Rejnmark L, Mosekilde L: Influence of hyper- and hypothyroidism, and the 

        effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int 

        2005; 77: 139-144.

101) Lauridsen A, Vestergaard P, Hermann AP, Brot C, Heickendorff L, Mosekilde L, Nexø E: 

        Plasma concentrations of 25-Hydroxy-Vitamin D and 1,25-Dihydroxy-Vitamin D are Related 

        to the Phenotype of Gc (Vitamin D-Binding Protein): A Cross-sectional Study on 595 Early 

        Postmenopausal Women. Calcif Tissue Int 2005; 77(1): 15-22.

100) Frost L, Hune LJ, Vestergaard P: Overweight and obesity as risk factors for atrial fibrillation 

        or flutter: The Danish Diet, Cancer, and Health Study. Am J Med 2005; 118: 489-495.

  99) Vestergaard P, Rejnmark L, Mosekilde L: Lægemiddelinformation: Cinacalcet – et nyt 

        medicinsk behandlingsprincip til sekundær hyperparathyreoidisme ved uræmi, parathyreoidea-

        cancer og primær hyperparathyreoidisme. Ugeskr Læger 2006: 168: 29-32.

  98) Vestergaard P: Prevalence and pathogenesis of osteoporosis in patients with inflammatory 

        bowel disease. Minerva Med 2004; 95(6): 469-480.

  97) Vestergaard P, Rejnmark L, Mosekilde L: Relative fracture risk in patients with diabetes 

        mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. 

        Diabetologia 2005; 48(7): 1292-1299.

  96) Vestergaard P, Rejnmark L, Mosekilde L: Fracture risk associated with oral and topical 

        corticosteroids. J Intern Med 2005; 257(4): 374-384.

  95) Vestergaard P, Rejnmark L, Mosekilde L: Reduced relative risk of fractures among users of 

        lithium. Calcified Tissue Int 2005; 77(1): 1-8.

  94) Mosekilde L, Rejnmark L, Vestergaard P: Strontium Ranelat (Protelos®) et nyt princip til 

        behandling af postmenopausal osteoporose. Ugeskr Læger 2005; 167(37): 3485-3487.

  93) Frost L, Vestergaard P: Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, 

        Cancer and Health Study. Am J Clin Nutr 2005; 81(3): 578-582.

  92) Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L: Effects of long-term 

        treatment with loop diuretics on bone mineral density, calcitropic hormones, and bone 

        turnover. J Intern Med 2005; 257: 176-184.

  91) Frost L, Vestergaard P: N-3 fatty acids consumed from fish and risk of atrial fibrillation or 

        flutter: The Danish Diet, Cancer and Health Cohort Study. Am J Clin Nutr 2005; 8(1): 50-54.

  90) Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch 

        Intern Med 2004; 164(18): 1993-1998.

  89) Rejnmark L, Vestergaard P, Mosekilde L: Reduced fracture risk in users of thiazide diuretics. 

        Calcified Tissue Int 2005; 76(3): 167-175.

  88) Frost L, Vestergaard P, Frost P: Work-related physical activity and risk of atrial fibrillation or 

        flutter: The Danish Diet, Cancer and Health Study. Occupational and Environmental Medicine 

        2005; 62(1): 49-53.

  87) Frost L, Vestergaard P: Trends in incidence and mortality in the hospital diagnosis of atrial 

         fibrillation in Denmark, 1980-1999, Int J Cardiology 2005; 103(1): 78-84.

  86) Vestergaard P, Rejnmark L, Mosekilde L, Fracture risk associated with use of anti-epileptic 

        drugs. Epilepsia 2004; 45(11): 1330-1337.

  85) Vestergaard P, Rejnmark L, Mosekilde L, Osteoporosis is markedly underdiagnosed – a 

        nationwide study from Denmark. Osteoporosis Int 2005; 16(2): 134-141.

  84) Rejnmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brixen K, Mosekilde 

        L. Fracture risk in perimenopausal women treated with beta-blockers. Calcified Tissue Int 

        2004; 75(5); 365-372.

  83) Rejnmark L, Vestergaard P, Tofteng CL, Kolthoff N, Stilgren LS, Brixen K, Mosekilde L. 

        Response rates to estrogen treatment in perimenopausal women: Five-year data from The 

        Danish Osteoporosis Prevention Study (DOPS). Maturitas 2004; 48(3): 307-320.

  82) Rejnmark L, Vestergaard P, Charles P, Herman P, Brot C, Eiken P, Mosekilde L. No effect of 

        Vitamin A intake on bone mineral density and fracture risk in perimenopausal women. 

        Osteoporosis Int 2004; 15: 872-880.

  81) Christensen PM, Sørensen HA, Vestergaard P: Vurdering af behandlingseffekter ved 

        behandling af osteoporose. Ugeskr Læger 2005; 167(9): 1031-1033.

  80) Nielsen LR, Vestergaard P, Mosekilde L: Lægemidler med sideeffekter, der påvirker 

         calciumhomøostasen, knoglemetabolismen og risikoen for frakturer. Ugeskr Læger 2005; 

        167(9): 1026-103

  79) Vestergaard P, Eiken P: Sekundær osteoporose, epidemiologi og risikofaktorer. 

        Ugeskr Læger 9102005; 167(9): 1020-1026.

  78) Bollerslev J, Øgard CG, Schwarz P, Vestergaard H, Vestergaard P: Behandling af primær 

        hyperparathyreoidisme, indikationer, symptomer komplikationer og prognose. Ugeskr Læger 

        2005; 167(8): -914.

  77) Vestergaard P, Laursen L, Schwarz P, Brixen K: Glucocorticoidinduceret osteoporose: 

        forekomst, profylakse og behandling. Ugeskr Læger 2005; 167(8): 898-900.

  76) Vestergaard P, Mosekilde L, Brixen K: Antiresorptiv behandling ved osteoporose. Ugeskr 

        Læger 2005; 167(8): 883-887.

  75) Vestergaard P, Kristensen K, Bruun JM, Østergaard JR, Heickendorf